Generic Semaglutide in Canada

Generic semaglutide refers to Health Canada-approved generic versions of injectable semaglutide, the active molecule in Ozempic. Canada approved two generics: Plosbrio (Dr. Reddy's Laboratories) and Poviztra (Apotex, Canada's largest generic manufacturer). Both are bioequivalent to Ozempic and expected to cost 45-90% less.

Yes, in terms of active ingredient. Generic semaglutide contains the same active molecule (semaglutide) at the same doses (0.5 mg, 1 mg, 2 mg). Health Canada requires bioequivalence, meaning the generic delivers the same amount of drug into the bloodstream at the same rate as the reference product (Ozempic). The pen device and excipients may differ slightly between manufacturers.

Health Canada estimates generic semaglutide will be 45-90% cheaper than brand-name Ozempic. At launch, prices may be closer to 25-40% below brand. As more generics enter the market and production scales over 12-24 months, prices are expected to fall further. MyRocky currently offers generic semaglutide from $149/month.

Generic semaglutide (Plosbrio and Poviztra) is approved for adults with type 2 diabetes. Physicians can also prescribe it off-label for weight management, as they do with Ozempic. A licensed Canadian physician must conduct a clinical assessment before prescribing. Eligibility typically requires a BMI of 30 or higher, or 27 or higher with a weight-related health condition.

No. Unlike the United States, Health Canada does not permit compounded versions of GLP-1 weight loss injections such as compounded semaglutide or tirzepatide. Canadian providers offer only Health Canada-approved products, either brand-name medications (Ozempic, Wegovy, Saxenda) or the newly approved generics (Plosbrio, Poviztra).